A61K 47/6899
Antibody-directed enzyme prodrug therapy [adept]
Official title: {Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}
A61K47/6899 (Antibody-directed enzyme prodrug therapy [adept]) appears on 86 US grants and 71 published applications in this corpus.
Search patents in A61K- Granted patents
- 86
- Published applications
- 71
- Assignees
- 66
- Inventors
- 208
- Latest grant
- 9 Jun 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 5 | 0 |
| 2000 | 6 | 0 |
| 2001 | 6 | 0 |
| 2002 | 6 | 8 |
| 2003 | 2 | 8 |
| 2004 | 2 | 7 |
| 2005 | 7 | 4 |
| 2006 | 3 | 7 |
| 2007 | 4 | 9 |
| 2008 | 3 | 1 |
| 2009 | 2 | 4 |
| 2010 | 4 | 3 |
| 2011 | 1 | 2 |
| 2012 | 3 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 5 | 6 |
| 2016 | 0 | 1 |
| 2017 | 2 | 1 |
| 2018 | 3 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Antibodies having specificity to nectin-4 and uses thereof9 Jun 2020US 10,675,357 B2Centre National de la Recherche Scientifique (CNRS)
- Antibody-drug conjugate having improved stability and use thereof11 Sep 2018US 10,071,170 B2Ablbio
- Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines)17 Apr 2018US 9,944,708 B2BioNTech SE
- Targeting and in vivo imaging of tumor-associated macrophages13 Mar 2018US 9,913,920 B2Vib Vzw
- Compounds and methods for the treatment of ERB B2/NEU positive diseases22 Aug 2017US 9,737,616 B2Bio-Thera Solutions, Ltd.
- Compositions and methods for modulation of antibody activity16 May 2024US 2024/0156974 A1
- Protein therapeutics for treatment of senescent cells8 Sep 2022US 2022/0282399 A1BioAtla, Inc.
- Single-domain antibody-cytosine deaminase fusion proteins24 Feb 2022US 2022/0056149 A1Lumosa Therapeutics Co., Ltd.
- Protein therapeutics for treatment of senescent cells29 Jul 2021US 2021/0230221 A1BioAtla, Inc.
- Single-domain antibody-cytosine deaminase fusion proteins4 Jul 2019US 2019/0202931 A1Lumosa Therapeutics Co., Ltd.
Most cited
By later US patents
- Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells465US 4,975,278 ABristol-Myers Company · 1990
- Elongated and multiple spacers in activatible prodrugs154US 7,223,837 B2Syntarga B.V. · 2007
- Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods108US 6,451,995 B1Sloan-Kettering Institute for Cancer Research · 2002
- Prodrugs for enzyme mediated activation103US 5,621,002 ABehringwerke Aktiengesellschaft · 1997
- Site specific in vivo activation of therapeutic drugs73US 5,433,955 AAkzo N. V. · 1995